Hormonothérapie combinée à la radiothérapie externe dans le cancer de prostate localement avancé : les effets secondaires contrecarrent-ils les bénéfices ?

25 juin 2010

Auteurs : S.J. Drouin, M. Rouprêt, A. Bossi, M. Bolla
Référence : Prog Urol, 2010, 20, S186, suppl. S3




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Bria E., Cuppone F., Giannarelli D., Milella M., Ruggeri E.M., Sperduti I., et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials Cancer 2009 ;  115 : 3446-3456 [cross-ref]
Zagars G.K., Johnson D.E., von Eschenbach A.C., Hussey D.H. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study Int J Radiat Oncol Biol Phys 1988 ;  14 : 1085-1091 [cross-ref]
Boccon-Gibod L., Richaud P., Coloby P., Coulange C., Culine S., Davin J.L., et al. First line indications for hormonal therapy in prostate cancer Prog Urol 2010 ;  20 : 109-115 [cross-ref]
Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer JAMA 2005 ;  294 : 238-244 [cross-ref]
Shelley M.D., Kumar S., Coles B., Wilt T., Staffurth J., Mason M.D. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials Cancer Treat Rev 2009 ;  35 : 540-546 [cross-ref]
Tunn U.W., Wiedey K. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe Prostate Cancer Prostatic Dis 2009 ;  12 : 83-87 [cross-ref]
Holzbeierlein J.M. Managing complications of androgen deprivation therapy for prostate cancer Urol Clin North Am 2006 ;  33 : 181-190 [inter-ref]
Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., Stratte P.T. Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 2000 ;  163 : 181-186 [cross-ref]
Smith M.R., Lee W.C., Brandman J., Wang Q., Botteman M., Pashos C.L. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 2005 ;  23 : 7897-7903 [cross-ref]
Braga-Basaria M., Dobs A.S., Muller D.C., Carducci M.A., John M., Egan J., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy J Clin Oncol 2006 ;  24 : 3979-3983 [cross-ref]
Glode L.M. Metabolic syndrome and prostate cancer Cancer 2008 ;  112 : 2103-2105 [cross-ref]
Derweesh I.H., Diblasio C.J., Kincade M.C., Malcolm J.B., Lamar K.D., Patterson A.L., et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer BJU International 2007 ;  100 : 1060-1065
D’Amico A.V., Denham J.W., Crook J., Chen M.H., Goldhaber S.Z., Lamb D.S., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 2007 ;  25 : 2420-2425
Keating N.L., O’Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 2006 ;  24 : 4448-4456 [cross-ref]
Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., Litwin M.S. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 2007 ;  110 : 1493-1500 [cross-ref]
Bolla M., de Reijke T.M., Van Tienhoven G., Van den Bergh A.C., Oddens J., Poortmans P.M., et al. Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 2009 ;  360 : 2516-2527 [cross-ref]
Bolla M., van Tienhoven G., de Reijke T.M., van den Bergh A.C., van der Meijden A.P., Poortmans P.M., et al. EORTC Radiation Oncology and Genito-Urinary TractCancer Groups Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT – -Results of the randomized EORTC Phase III trial 22961 J Clin Oncol 2007 ; 5014ASCO Meeting Abstracts.
Hanks G.E., Pajak T.F., Porter A., Grignon D., Brereton H., Venkatesan V., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 2003 ;  21 : 3972-3978 [cross-ref]
Efstathiou J.A., Bae K., Shipley W.U., Hanks G.E., Pilepich M.V., Sandler H.M., et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02 Eur Urol 2008 ;  54 : 816-823 [cross-ref]
Lawton C.A., Winter K., Murray K., Machtay M., Mesic J.B., Hanks G.E., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 2001 ;  49 : 937-946 [cross-ref]
Wirth M.P., Weissbach L., Marx F.J., Heckl W., Jellinghaus W., Riedmiller H., et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer Eur Urol 2004 ;  45 : 267-270 [cross-ref]
Efstathiou J.A., Bae K., Shipley W.U., Hanks G.E., Pilepich M.V., Sandler H.M., et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 2009 ;  27 : 92-99 [cross-ref]
Bolla M., Colette G., Van Tienhoven G., Warde P., Dubois J.B., Mirimanoff R.O., et al. Ten years results of long terme adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study Int J Radiat Oncol Biol Phys 2008 ;  72 (Suppl 1) : S30
Nguyen P.L., Chen M.H., Renshaw A.A., Loffredo M., Kantoff P.W. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: Implications for Screening Recommendations Int J Radiat Oncol Biol Phys 2009 ; [Epub ahead of print].






© 2010 
Elsevier Masson SAS. Tous droits réservés.